NCT00795353View on ClinicalTrials.gov

Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis

TerminatedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Chronic Plaque Psoriasis
Interventions
DRUG

Amevive exposure

Commercial alefacept prescribed by Physician

Trial Locations (21)

T6J 5E5

Edmonton

R3C 0N2

Winnipeg

R3C 1R4

Winnipeg

E1A 2YA

Bathurst

E2E 4Y7

Quispamsis

A1B 3E1

St. John's

A1C 2H5

St. John's

B3H 1Z4

Halifax

L8K 6R5

Hamilton

N6A 3H7

London

N6H 1S9

London

L3P 1A8

Markham

L6J 7W5

Oakville

K9J 1Z2

Peterborough

M4V2V6

Toronto

N2J 1C4

Waterloo

L3C 3W4

Welland

G8B 2V5

Alma

H2K 4L5

Montreal

G1J 1X7

Québec

J2S 6L6

Saint-Hyacinthe

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00795353 - Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter